RxDoctor Payments Data

Peter Nguyen, MD

Internal Medicine · Victoria, TXNPI 1902976483

Payments from drug & device makers

$70,146in general payments, 2019–2025

Across 193 payments — averaging $363.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Canada Ltd.ltee$39K
  • Acerus Pharmaceuticals Corporation$10K
  • Idorsia Pharmaceuticals US Inc$9K
  • Boehringer Ingelheim$9K
  • Novo Nordisk$687
  • Amgen$262
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$8,41171%
  • Travel & lodging$3493%
  • Food & beverage$2,98025%
  • Education$1301%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,146 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$312,966
Medicare patients
603
Services billed
3,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin19$18,128
JanuviaSitagliptin Phosphate15$17,046
XareltoRivaroxaban14$8,293
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen112$2,162
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,797
Famotidine50$1,179
Atorvastatin Calcium99$920
Pregabalin44$903
Losartan Potassium68$809
Rosuvastatin Calcium56$742
Zolpidem Tartrate98$728
Tramadol Hcl121$690
Pantoprazole Sodium55$656
Acetaminophen-CodeineAcetaminophen With Codeine41$621
NitrofurantoinNitrofurantoin Macrocrystal12$586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta$8,705$18,12819 claims
Johnson & JohnsonXarelto$216$8,29314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →